Skip to main content
Premium Trial:

Request an Annual Quote

IDbyDNA Raises $20M in Series B Financing

NEW YORK – Metagenomics technology company IDbyDNA announced Wednesday it has raised $20 million in a Series B financing round. Artis Ventures led the round, joined by Genesys Capital and other investors.

The firm said in a statement it will use the funds to enhance and expand its Explify software platform and to support the opening of a CLIA-approved commercial laboratory.

The University of Utah spinout is based in San Francisco with a lab in Salt Lake City, Utah. Its Explify next-generation sequencing-based diagnostics platform identifies more than 50,000 microorganisms — including more than 3,000 pathogens. It can also quantify and detect antimicrobial resistance, the firm said.

"We believe IDbyDNA's technology has hit a tipping point and is now set to revolutionize the way we respond to, and tackle, infectious disease outbreaks, and address the growing concerns of antimicrobial resistance," Stuart Peterson, partner at Artis Ventures, said in a statement. Artis Ventures also led IDbyDNA's $9 million Series A funding round.

In 2018, IDbyDNA licensed Explify to Brazil-based Fleury Group and partnered with Rady Children's Institute for Genomic Medicine on a clinical trial using Explify to diagnose central nervous system infections in pediatric patients.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.